Spyre公布其潜在同类最佳药物Spy002(抗TL1A)在Skyline试验中治疗中重度溃疡性结肠炎患者的A部分诱导结果

美股速递
Jun 15

Spyre Therapeutics公司宣布,其候选药物Spy002(一种抗TL1A疗法)在针对中重度溃疡性结肠炎患者的Skyline试验中,取得了A部分的诱导期结果。数据显示,该药物展现出成为同类最佳疗法的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10